Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Sanofi, RadioMedix, Orano Med Announce Agreement on Radioligand Medicine for Cancers
Details : Sanofi will be responsible for the global commercialization of AlphaMedix (212Pb-DOTAMTATE), while Orano will manufacture AlphaMedix through its global industrial platform currently under development.
Product Name : Alphamedix
Product Type : Peptide
Upfront Cash : $111.6 million
December 09, 2024
Lead Product(s) : 212-Pb Dotamtate
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : RadioMedix
Deal Size : Inapplicable
Deal Type : Inapplicable
RadioMedix and Orano Med Receive Breakthrough Designation for AlphaMedixTM
Details : AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy for unresectable, metastatic gastroenteropancreatic neuroendocrine tumors, naïve to peptide receptor therapy.
Product Name : Alphamedix
Product Type : Peptide
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : 212-Pb Dotamtate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : RadioMedix
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MP0712
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Molecular Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
Molecular and Orano Med Shares Preclinical Data of DLL3-Targeting Radio-DARPin Therapy
Details : MP0712 is a DLL3-targeting radio-DARPin therapy candidate, which is currently being evaluated for the treatment of
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2024
Lead Product(s) : MP0712
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Molecular Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi and Orano Join Forces to Develop Next-Generation Radioligand Medicines
Details : The agreement aims to combine Sanofi and Orano's expertise against rare cancers and accelerate the development of next-generation radioligand medicines based on 212Pb alpha-emitting isotopes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Crescendo Biologics Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Orano Med Enters Pre-Clinical Collaboration With Crescendo Biologics
Details : The collaboration focuses on exemplify the benefit of Orano Med’s Targeted Alpha Therapies, using Humabody VH for precise targeting.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 07, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Crescendo Biologics Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : 48Hour Discovery
Deal Size : Undisclosed
Deal Type : Partnership
Orano Med and 48Hour to Develop Novel Peptide Receptor Radionuclide for Targeted Cancer
Details : Partnership aims to harness the potent properties of lead-212 (212Pb), a rare alpha-emitting radioisotope, in conjunction with 48Hour Discovery’s innovative peptide discovery technology and expertise.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : 48Hour Discovery
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : MP0712
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Molecular Partners
Deal Size : Undisclosed
Deal Type : Collaboration
Molecular and Orano Med's Co-Development Agreement for Radio-DARPin Therapies
Details : The Collaboration focuses on developing novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to kill cancer cells selectively.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2024
Lead Product(s) : MP0712
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Molecular Partners
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Orbit Discovery
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Orbit Discovery
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 212-Pb Dotamtate
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : RadioMedix
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitt...
Product Name : Alphamedix
Product Type : Peptide
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : 212-Pb Dotamtate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : RadioMedix
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 212Pb-GRPR is a 212Pb-conjugated anti-GRPR (Gastrin-Releasing Peptide Receptor) targeting different types of solid tumors including several breast and prostate cancers tumor types.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
April 01, 2023